Biovance Capital
VC Fund
Lisbon, Portugal
Biovance Capital is a new € 51M fund to invest in early-stage biotech companies across Europe developing innovative therapeutics in all disease areas and drug modalities (small and large molecules, vaccines, cell, and gene therapies).
- Total investments:
- 4
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Biovance Capital invests in
Stages Biovance Capital invests in
Countries Biovance Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Investment Focus
Industry
- Medical 2 (50%)
- Biotechnology 2 (50%)
- Product Research 1 (25%)
Stage
- Seed 1 (25%)
- Series A 1 (25%)
Country
- Portugal 1 (25%)
- The Netherlands 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Joao Incio
General Partner
|
General Partner | Total investments: 2 | Find email | |
Ricardo Perdigão Henriques
Managing Partner
|
Managing Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Laigo Bio
|
Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $6.4M / Seed / Mar 23, 2026 | |
Mondego Bio
|
Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. | Series A / Sep 18, 2025 | |
|
Mondego Bio
|
Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. | Series A / Sep 18, 2025 | |
|
Mondego Bio
|
Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. | Series A / Sep 18, 2025 |
Co-Investors
OrbiMed
3 deals together
Torrey Pines Investment
3 deals together
Angelini Ventures
1 deal together
ARGOBIO
1 deal together
Cancer Research Horizons
1 deal together
Curie Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Biovance Capital invest in?
Biovance Capital invests primarily in Medical, Biotechnology and Product Research startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in Portugal. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Biovance Capital?
Public channels for Biovance Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Biovance Capital?
The team at Biovance Capital includes Joao Incio (General Partner) and Ricardo Perdigão Henriques (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
